Acquisition and Research Funding Collaboration Agreement (Details) - USD ($)			1 Months Ended	3 Months Ended		92 Months Ended
		Jan. 29, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development	[1]			$ 107,016,000	$ 128,816,000
Reduction to research and development expense				0
Deferred research funding liability, current				12,500,000		$ 12,500,000	$ 0
Collaboration And Development Funding Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement, aggregate consideration amount (up to)		$ 75,000,000
Deferred liability, upfront payment		$ 12,500,000
Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development						$ 49,800,000
Collaborative Arrangement with F-Star and Acquisition of F-Star Gamma | Contingent Payments Upon Achievement of Specialized Clinical Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration payment triggered			$ 30,000,000
Contingent consideration recognized				$ 0

[1] Includes expenses for cost sharing payments due to a related party of $4.2 million for the three months ended March 31, 2023.